# Centers for Disease Control and Prevention Center for Surveillance, Epidemiology, and Laboratory Services



### **Public Health Surveillance**

Lesliann Helmus, MS, CHTS-CP

**Associate Director for Surveillance** 

**Division of Health Informatics and Surveillance** 

**U.S. Centers for Disease Control and Prevention** 

October 28, 2021

## **Outline**

- Public Health Surveillance
  - Considerations
  - Case Surveillance
  - Syndromic Surveillance
- Evolving Technologies for Public Health Surveillance



## **Definition of Public Health Surveillance**



"The ongoing, systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice, closely integrated with the timely dissemination of these data to those who need to know."

~Ehrenkranz, NJ Am J Med 1981

## **Uses of Public Health Surveillance Data**

#### DETECT

- Illness and injuries
- Outbreaks and epidemics

#### **CHARACTERIZE**

- Magnitude, trends, populations at risk
- Assess healthcare utilization

#### **MONITOR**

- Study etiology, natural history, risk factors
- Track and manage cases

### **RESPOND**

- Implement interventions; target resources
- Evaluate prevention and control measures

In public health, we can't do anything without surveillance. That's where public health begins.

David Satcher, MD, PhDDirector, CDC 1993-1998



## **Implementing Public Health Surveillance**

**Define Objectives** 

• Intended use, audience, actions

**Identify Strategies** 

 Authority, data sources, inclusion criteria, data management

Plan Analysis and Dissemination

Measures, presentation

**Evaluate and Refine** 

• Valid, timely, complete, efficient

## **Surveillance Methods and Data Sources**

- Case reporting (clinical, lab, epi)
- Lab test result reporting
- Registries (e.g., cancer, exposures, vaccine)
- Vital registration (deaths, births)
- Syndromic surveillance (emergency department, urgent care, EMS)
- Vector surveillance
- Risk factor and disease prevalence surveys
- Environmental monitoring (air pollution, weather)
- Genomic surveillance (host and pathogen genomes)
- Secondary data (claims, social media, mobility)

Methods and data sources should be determined by the public health need

## **Case-Based Surveillance**

- Case definitions establish the events of interest
  - Clinical criteria signs and symptoms
  - Laboratory criteria test results
  - Epidemiologic linkage contact with a known case
  - Death-related criteria primary or underlying cause of death
  - Other age groups, settings (e.g., work-related), geographic areas, etc.
- Automating detection and classification can
  - Increase completeness
  - Improve timeliness
  - Reduce burden

## **Case-Based Disease Surveillance Data**



#### **Problems**

- •ICD-9 / ICD-10 diagnosis codes
- Problem description
- Signs and symptoms



#### **Patients**

- Patient age
- Sex
- Socio-demographics
- Geographic



#### **Health Care Services**

- •CPT procedure codes
- Hospitalizations



#### **Lab Tests and Results**

- Panel and test name
- •Value, units, reference ranges
- •LOINC



#### **Vaccines**

- Vaccines administered
- Dose, units, quantities, strength
- History



#### **Risk Factors**

- Behaviors
- Travel
- Environmental
- Genetic



#### **Medications**

- Prescriptions/administrations
- Dose, units, quantities, strength

| 166             |
|-----------------|
|                 |
| 111///          |
| ON THE BUILDING |
|                 |

Patient first name



Patient last name


#### Human Infection with 2019 Novel Coronavirus Case Report Form

Date of birth (MM/DD/YYYY): \_\_\_


| Reporting Jurisdiction  |                |                               | Case state/  | local ID  |                               |                        |  |
|---|----------------|-------------------------------|--|---|-------------------------------|------------------------|--|
| Reporting Health Department   |                |                               | CDC 2019-n   | CoV ID  |                               |                        |  |
| Contact ID <sup>a</sup>   |                |                               | NNDSS loc. rec. ID/Case ID <sup>b</sup>  |   |                               |                        |  |
| <sup>a</sup> Only complete if case-patient is a known contact of prior source case-patient. Assign Contact ID using CDC 2019-nCoV ID and sequential contact ID, e.g., Confirmed case CA102034567 has contacts CA102034567 -01 and CA102034567 -02. <sup>b</sup> For NNDSS reporters, use GenV2 or NETSS patient identifier. |                |                               |  |   |                               |                        |  |
| Interviewer Information   |                |                               |  |   |                               |                        |  |
| Name of Interviewer: Last: First:   |                |                               | Telephone:   | one: Email:   |                               |                        |  |
| Affiliation/Organization:   |                |                               |  |   |                               |                        |  |
| Case Classification and Identification  |                |                               |  |   |                               |                        |  |
| What is the current status of this person?  |                |                               |  | Under what process w  | as the case first identified? | (check all that apply) |  |
| ☐ Lab-confirmed case* ☐ Probable case   |                |                               |  | Clinical evaluation   | Routin                        | e surveillance         |  |
| If probable, select reason for case classification:   |                |                               |  | Contact tracing of case patient Other, specify:               |                               |                        |  |
| ☐ Meets clinical criteria AND epidemiologic evidence with no confirmatory lab testing*  |                |                               |  | EpiX notification of travelers. If yes, DGMQID:               |                               |                        |  |
| Meets presumptive lab evidence <sup>±</sup> AND either clinical criteria OR epidemiologic evidence  |                |                               |  | Unknown   |                               |                        |  |
| Meets vital records criteria with no confirmatory lab testing   |                |                               |  | Report date of case to CDC (MM/DD/YYYY):                      |                               |                        |  |
| *Detection of SARS-CoV-2 RNA in a clinical specimen using a molecular amplification detection t   |                |                               |  | Data of first a siting and income all atting (AMA/DD (AMA/DD) |                               |                        |  |
| <sup>±</sup> Detection of specific antigen in a clinical specimen, OR detection of specific antibody in splasma, or whole blood indicative of a new or recent infection   |                |                               |  |   |                               |                        |  |
| plasma, or whole blood mulcative or a new or recent infection   |                |                               |  |   |                               |                        |  |
| Hospitalization, ICU, and Death Information  Was the patient hospitalized? If hospitalized, was a translator required? Was the patient admitted to an intensive care unit (ICU)?  |                |                               |  |   |                               |                        |  |
|   |                |                               |  | Yes No Unknown  |                               |                        |  |
| If yes, admission date 1 di   | scharge date 1 | If yes, specify which languag | e: If yes, admission date 1 discharge date 1   |   |                               | date 1                 |  |
| //(MM/DD/YYYY) _  | JJ             |                               | <u> </u>   | // (MM/DD/YYYY)//   |                               |                        |  |
| Did the patient die as a result of this illness?  |                |                               |  |   |                               |                        |  |
| Yes No Unknown If yes, date of death (MM/DD/YYYY):/ Unknown date  |                |                               |  |   |                               |                        |  |
| Case Demographics   |                |                               |  |   |                               |                        |  |
| Date of birth (MM/DD/YYYY):/ Sex:   |                |                               |  |   | ce (check all that apply):    |                        |  |
| Age: Age units (yr/mo/day):   |                |                               | Hispanic/Latino Black White Asian  Non-Hispanic/Latino American Indian/Alaska Native |   |                               |                        |  |
|   |                |                               |  | Unknown Native Hawaiian/Other Pacific Islander                |                               |                        |  |
| Does this case have any tribal affiliation?   |                |                               |  |   | Unknown Other, s              | pecify:                |  |
| Which would best describe where the patient was staying at the time of illness onset?   |                |                               |  |   |                               |                        |  |
| ☐ House/single family home ☐ Hotel/motel ☐ Nursing home/assisted living facility ☐ Rehabilitation facility ☐ Mobile home  |                |                               |  |   |                               |                        |  |
| Apartment   |                |                               |  |   |                               |                        |  |
| Homeless shelter Outside, in a car, or other location not meant for human habitation Other (specify): Unknown   |                |                               |  |   |                               |                        |  |

# **Traditional Case Report**


## **Case-Based Disease Surveillance**




# Daily Trends in COVID-19 Cases in the United States



United States COVID-19 7-Day Case Rate per 100K by State/Territory





US: The most recent line level case record was reported during the week ending on Oct 23, 2021. Percentage of deaths among reported cases - 1.64%. Percentage of deaths reporting race by date - 81.17%.

US territories are included in case and death counts but not in population counts. Potential two-week delay in case reporting to CDC denoted by gray bars. Al = American Indian, AN = Alaska Native, NH = Non-Hispanic, PI = Pacific Islander. Excludes cases with unknown or multiple races.


<sup>\*</sup>Case Earliest Date is the earliest of the clinical date (related to illness or specimen collection and chosen by a defined hierarchy) and the Date Received by CDC. The date for the current week extends through Saturday.

Last Updated: Oct 21, 2021

Source: CDC COVID-19 Case Line-Level Data, 2019 US Census, HHS Protect; Visualization: Data, Analytics & Visualization Task Force and CDC CPR DEO Situational Awareness Public Health Science Team

## **Syndromic Surveillance**

#### **Automated Data Collection and Syndrome Detection**



- Define new syndromes for new questions
- Useful when other data are not available
- Integrate with other data for more complete picture

# **Syndromic Surveillance**

#### Early alerts for many different health events



Emerging infectious diseases and outbreaks



Mass gatherings and their situational needs



Chronic diseases and their complications



Environmental conditions and their impact



Injury issues (drownings, overdoses)




Natural and manmade disaster response needs

# **Shared Syndrome Definitions**

### Opioid v2 ESSENCE code

(,^narcan^,or,^naloxo^,or,^[;/ ]T40.[012346][X09][14]A^,or,^[;/ ]T40[012346][X09][14]A^,or,^[;/ ]F11.12[0129]^,or,^[;/ ]F11.22[0129]^,or,^[;/ ]F11.92[0129]^,or,^[;/ [F1112[0129]^,or,^[;/ ]F1122[0129]^,or,^[;/ ]F1192[0129]^,or,^[;/ ]965.0[0129][;/]^,or,^[;/ ]9650[0129][;/]^,or,^[;/ ]E850.[012]^,or,^[;/ [E850[012]^,or,^295174006^,or,^295175007^,or,^295176008^,or,^295165009^,or,^242253008^,or,^297199006^,or,^295213004^,),or,(,(,(,^poison^,or,^verdo[se][se] ^,or,^over dose^,or,^overose^,or,^nodding^,or,^ nod ^,or,^snort^,or,^in[gj]est^,or,^intoxic^,or,^unresponsiv^,or,^loss of consciousness^,or,^syncop^,or,^shortness of breath^,or,^short of breath^,or,^altered mental status^,) ,and, (,^her[io][oi]n^,or,^ hod ^,or,^speedball^,or,^speed ball^,or,^dope^,or,^opioid^,or,^op[io][oi]d^,or,^opiate^,or,^op[iu][ui]m^,or,^opum^,or,^methadone^,or,^suboxone^,or,^oxyco^,or,^oxyi^,or,^ oxy ^,or,^percoc^,or,^vicod^,or,^fent^,or,^hydrocod^,or,^morphin^,or,^cod[ei][ie]n^,or,^codene^,or,^oxymor^,or,^dilaud^,or,^hydromor^,or,^tramad^,or,^suboxin^,or,^ buprenorphine^,or,^Abstral^,or,^Actiq^,or,^Avinza^,or,^Butrans^,or,^Demer[oa]l^,or,^Dolophine^,or,^Duragesic^,or,^Fentora ^,or,^Hysingla^,or,^Methadose^,or,^ Morphabond^,or,^Nucynta^,or,^Onsolis^,or,^Oramorph^,or,^Oxaydo^,or,^Roxanol^,or,^Sublimaze^,or,^Xtampza^,or,^Zohydro^,or,^Anexsia ^,or,^Co-Gesic^,or,^Embeda ^,or,^Exalgo^,or,^Hycet^,or,^Hycodan^,or,^Hydromet^,or,^Ibudone^,or,^Kadian^,or,^Liquicet^,or,^Lorcet^,or,^Lortab^,or,^Maxidone^,or,^ MS Contin ^,or,^Norco ^,or,^ Opana ^,or,^Oxycet^,or,^Palladone^,or,^Percodan^,or,^Reprexain^,or,^Rezira^,or,^Roxicet^,or,^Targiniq^,or,^TussiCaps^,or,^ Tussione ^,or,^Tuzistra^,or,^Vicoprofen^,or,^Vituz^,or,^Xartemis^,or,^Xodol^,or,^Zolvit^,or,^Zutripro^,or,^Zydone^,or,^Ultram^,or,^[;/ ]F11.[129]0^,or,^[; /[F11[129]0^,),),andnot,(,^no loss of consciousness^,or,^denie[sd] loss of consciousness^,or,^negative loss of consciousness^,or,^denies any loss of consciousness^,or,^denies her[io][oi]n^,or,^deny her[io][oi]n^,or,^denied her[io][oi]n^,or,^denying her[io][oi]n^,or,^denies drug^,or,^deny drug^,or,^denied drug^,or,^denying drug^,or,^denies any drug^,or,^with dra^,or,^withdra^,or,^detoxification^,or,^detos^,or,^detoz^,or,^dtox^,or,^ oxy sat ^,or,^ oxy state ^,or,^oxy high^,or,^oxy low^,or,^oxy mask ^,or,^oxy given^,or,^given oxy ^,or,^oxy clean^,or,^low oxy ^,or,^high oxy ^,or,^placed on oxy ^,or,^pulse oxy ^,or,^oxy deep cleaner^,or,^not enough oxy ^,or,^oxy level^,or,^sedat ^,or,^received fentanyl^,or,^administered fentanyl^,or,^given fentanyl^,or,^fentanyl en route^,or,^fentanyl enrt^,or,^fent en route^,or,^fentanyl given^,or,^fentynl given^,or,^gave fent^,or,^gave fentanyl^,or,^given fentanly^,or,^mcg fentanyl^,or,^mcg fent^,or,^mcg of fent^,or,^fentanyl 75^,or,^fentanyl 50^,or,^50 fentanyl^,or,^fentanyl 100^,or,^100 fentanyl^,or,^fentanyl 150^,or,^intranasal fent^,or,^milligram fent^,or,^milligram of fentanyl^,or,^ fenton ^,or,^fent pta^,or,^fentanyl pta^,or,^fentynl 100 ^,or,^fentynyl 100^,or,^fentynal 50^,or,^fentynl 50^,or,^fent 50^,or,^fent 100^,or,^fent 150^,or,^diffently^,or,^received fent ^,or,^recieved fent ^,or,^ given 50 ^,or,^ given 100 ^,or,^ given 150 ^,or,^ gave 50 ^,or,^ gave 100 ^,or,^ gave 150 ^,or, ^ doses of fent ^,),)

FIGURE 1. Quarterly rate\* of suspected opioid overdose, by U.S. region<sup>†</sup> — 52 jurisdictions in 45 states, National Syndromic Surveillance Program, July 2016–September 2017<sup>§</sup>



Abbreviation: ED = emergency department.

\* Per 10,000 ED visits.

Vital Signs: Trends in Emergency Department Visits for Suspected Opioid Overdoses

— United States, July 2016–September 2017

MMWR Weekly / March 9, 2018 / 67(9);279–285





Figure 4. ED Visits among Persons 11 to 34 Years of Age Who Received Diagnoses Potentially Related to EVALI, According to Sex.




Percentage of Emergency Department visits with Diagnosed COVID-19 in United States, by Age Group



Impact of the COVID-19 Pandemic on Emergency Department Visits — United States, January 1, 2019–May 30, 2020 MMWR Weekly / June 12, 2020 / 69(23);699–704

FIGURE 1. Weekly number of emergency department (ED) visits — National Syndromic Surveillance Program, United States,\*
January 1, 2019 – May 30, 2020<sup>†</sup>



<sup>\*</sup> Hawaii, South Dakota, and Wyoming are not included.

<sup>†</sup> Vertical lines indicate the beginning and end of the 4-week coronavirus disease 2019 (COVID-19) early pandemic period (March 29–April 25, 2020) and the comparison period (March 31–April 27, 2019).

# Public Health Reports Supplement on Syndromic Surveillance: July/August 2017

- Injuries/illness due to extreme weather events
- Medical needs after Hurricane Sandy (dialysis, oxygen)
- Underreporting of rabies exposures
- Drug overdoses and illnesses (opioids, synthetic cannabinoids, street drugs)
- Mass gathering surveillance (sports, religious, and political events)
- Unreported suspect meningococcal cases or unnecessary prophylaxis
- Ebola surveillance during the West African outbreak
- Suicide-related emergency department visits
- Veterans Affairs: Influenza-related telephone triage (real-time data)



## **Surveillance Challenges**



#### **Proliferation and Lack of Standards**

- Many surveillance systems and activities
- Little harmonization across diseases; many data collection formats



#### **Surveillance System Silos**

- Unrealized interoperability, shared services, and efficiencies
- Local/regional/national public health: many systems/requirements



#### **Innovation and Resources**

- Slow adoption of new technologies
- Insufficient workforce with the right skills in the right places




#### **Health Information Technology and Policies**

- Electronic Health Records; expanding data standards
- Data sharing

## **Public Health Digital Transformation**

As public health becomes more connected, there is an expectation of shorter time for data collection and analysis.



## What's New in Data Sources

Lifestyle / Mind and Body

You Could Soon Be Able to Send Data from Your Fitbit Straight to Your Doctor How Companies Scour Our Digital Lives for Clues to Our Health

An emerging field, digital phenotyping, tries to assess people's well-being based on their interactions with digital devices.

SundayReview | NEWS ANALYSIS

The Age of Big Data

Text messaging service could help reduce opioid relapses

SINGAPOR

Wastewater testing surveillance sites for Covid to double by next year

POLICY & ETHICS

Can the U.S. Get 1 Million People to Volunteer Their Genomes?

Open Source Data

# What's New in Data Capture and Exchange?

- Mobile technology, Internet panels
- Vocabulary/Terminology Standards
  - ICD9/10, LOINC, SNOMED, USCDI\*
- Content Standards
  - Health Level 7 International (HL7) standards
  - HL7 Clinical Document Architecture
  - Fast Healthcare Interoperability Resources (FHIR)
- Privacy Preserving Record Linkage (PPRL)




<sup>\*</sup>USCDI - United States Core Data for Interoperability (USCDI)

# What's New in Data Storage, Analysis, and Visualization?

- Big data (volume, complexity, velocity) cloud, data lakes
- Analytic tools analysis (SAS, R), coding (Python, Java), queries (SQL, Hadoop)
- Machine Learning, Natural Language Processing, Artificial Intelligence
- Data integration platforms DCIPHER, SEDRIC
- Visualization tools Tableau, R Shiny, Power BI
- Analysis and visualization platforms



### **Modernization Priorities**



# Build the right foundation

Provide the new information infrastructure and automated data sources for pandemicready data sharing

# Accelerate data into action

Create faster, more integrated use of data to have more real-time situational awareness and forecasts of health threats for greater prevention and response

# Develop a state-of the-art workforce

Identify, recruit, and retain experts in Health IT, Data Science, and Cybersecurity to generate meaningful public health insights

# Support + extend partnerships

Engage with healthcare, governmental, academic, and other partners to address policy challenges and create new strategic partnerships to solve problems

# Manage change + governance

Provide the necessary structure to support modernization and aid adoption of unified technology, data, and data products

# Questions?

For more information, contact CDC 1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

